Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation

被引:15
作者
Frei, CR
Burgess, DS
机构
[1] Univ Texas, Hlth Sci Ctr, Clin Pharm Programs, Dept Pharmacol, San Antonio, TX 78229 USA
[2] Univ Texas, Coll Pharm, Austin, TX 78712 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 09期
关键词
Monte Carlo simulation; pharmacodynamics; beta-lactam; fluoroquinolone; Streptococcus pneumoniae;
D O I
10.1592/phco.2005.25.9.1161
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To evaluate the pharmacodynamics of four intravenous antimicrobial regimens-ceftriaxone 1 g, gatifloxacin 400 mg, levofloxacin 500 mg, and levolloxacin 750 mg, each every 24 hours-against recent Streptococcus pneumoniae isolates. Design. Pharmacodynamic analysis using Monte Carlo simulation. Data Source. The Surveillance Network (TSN) 2002 database. Measurements and Main Results: Streptococcus pneumoniae isolates (7866 isolates) were stratified according to penicillin susceptibilities as follows: susceptible (4593), intermediate (1986), and resistant (1287). Risk analysis software was used to simulate 10,000 patients by integrating published pharmacokinetic parameters, their variability, and minimum inhibitory concentration (MIC) distributions from the TSN database. Probability of target attainment was determined for percentage of time above the MIC (%T > MIC) from 0-100% for ceftriaxone and area under the concentration-time curve (AUC):MIC ratio from 0-150 for the fluoroquinolones. For ceftriaxone, probability of target attainment remained 90% or greater against the three isolate groups until a %T > MIC of 70% or greater, and it remained 90% or greater against susceptible and intermediate isolates over the entire interval (%T>MIC 0-100%). For levofloxacin 500 mg, probability of target attainment was 90% at an AUC:MIC ! 30, but the curve declined sharply with further increases in pharmacodynamic target. Levofloxacin 750 mg achieved a probability of target attainment of 99% at an AUC:MIC ratio ! 30; the probability remained approximately 90% until a target of 70 or greater, when it declined steeply. Gatifloxacin demonstrated a high probability (99%) of target attainment at an AUC:MIC ratio >= 30, and it remained above 90% until a target of 70. Conclusion. Ceftriaxone maintained high probability of target attainment over a broad range of pharmacodynamic targets regardless of penicillin susceptibility (%T > MIC 0-60%). Levofloxacin 500 mg maintained high probability of target attainment for AUC:MIC ratios 0-30; whereas, levofloxacin 750 mg and gatifloxacin maintained high probability of target attainment for AUC:MIC ratios 0-60. Rate of decline in the pharmacodynamic curve was most pronounced for the two levofloxacin regimens and more gradual for gatifloxacin and ceftriaxone.
引用
收藏
页码:1161 / 1167
页数:7
相关论文
共 24 条
[1]   The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs:: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae [J].
Ambrose, PG ;
Grasela, DM .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :151-157
[2]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[3]  
[Anonymous], 2002, M100S12 NCCLS
[4]   Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 [J].
Brueggemann, AB ;
Coffman, SL ;
Rhomberg, P ;
Huynh, H ;
Almer, L ;
Nilius, A ;
Flamm, R ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :680-688
[5]   Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[6]   Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers [J].
Chiu, LM ;
Menhinick, AM ;
Johnson, PW ;
Amsden, GW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1075-1079
[7]   Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers [J].
Chow, AT ;
Fowler, C ;
Williams, RR ;
Morgan, N ;
Kaminski, S ;
Natarajan, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2122-2125
[8]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[9]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[10]   The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada -: 1997 results from the SENTRY Antimicrobial Surveillance Program [J].
Doern, GV ;
Pfaller, MA ;
Erwin, ME ;
Brueggemann, AB ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (04) :313-316